Kezar Life Sciences, Inc. (KZR)

Market Cap	53.86M +55.2%
Revenue (ttm)	n/a
Net Income	-45.23M
EPS	-6.17
Shares Out	7.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	616,015
Open	7.36
Previous Close	n/a
Day's Range	7.27 - 7.47
52-Week Range	3.53 - 7.55
Beta	0.41
Analysts	Hold
Price Target	6.00 (-17.7%)
Earnings Date	May 11, 2026

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR
• Website: https://www.kezarlifesciences.com

Analyst Summary

According to 4 analysts, the average rating for KZR stock is "Hold." The 12-month stock price target is $6.0, which is a decrease of -17.70% from the latest price.

Price Target

$6.0

(-17.70% downside)

Analyst Consensus: Hold